-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

Benzinga·09/08/2026 14:57:42
Listen to the news
RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $198 price target.